Stryker Q1 organic sales +13.6%; raises FY growth guidance to 8-9%

STRYKER CORP

2023-Q1 EPS reported $1.54 revenue$4,778,000,000

Reported net sales $4.8B, +11.8% reported, +13.6% organic; MedSurg/Neuro +12.4%, Ortho+Spine +15.2%.
Adjusted EPS $2.14 (+8.6% YoY); reported EPS $1.54 (+83.3% on lower prior year).
Adjusted operating margin 21.1% contracted 70 bps YoY.
Raises FY 2023 organic net sales growth guidance to 8.0-9.0% (from prior implied).
Guides FY 2023 adjusted EPS to $10.05-$10.25.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

STRYKER CORP reported the first quarter of 2023 results: revenue $4.8 billion, net income $592 million, EPS $1.54.

Period: the first quarter of 2023
Revenue: $4.8 billion
Net income: $592 million
EPS: $1.54
Result: reported results

Exact text from the filing

Reported net sales increased 11.8% to $4.8 billion

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

STRYKER CORP reported full year 2023 results: EPS $10.05 to $10.25.

Period: full year 2023
EPS: $10.05 to $10.25
Result: guidance update

Exact text from the filing

we now expect full year 2023 organic net sales growth (2) to be in the range of 8.0% to 9.0% and expect adjusted net earnings per diluted share (2) to be in the range of $10.05 to $10.25.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

STRYKER CORP filing history →

Source: SEC EDGAR

accession 0000310764-23-000065

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.